Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets.

C P Leith1, C M Spier, T M Grogan

  • 1Department of Pathology, University of Arizona, Tucson.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 1, 1992
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex is not gender and why it matters for population health.

British journal of anaesthesia·2018
Same author

Improving bone marrow biopsy quality through peer discussion and data comparisons: A single institution experience.

International journal of laboratory hematology·2018
Same author

[Allogeneic transplants for biological reconstruction of bone defects].

Der Orthopade·2017
Same author

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

Leukemia & lymphoma·2016
Same author

ICARUSS, the Integrated Care for the Reduction of Secondary Stroke trial: rationale and design of a randomized controlled trial of a multimodal intervention to prevent recurrent stroke in patients with a recent cerebrovascular event, ACTRN = 12611000264987.

International journal of stroke : official journal of the International Stroke Society·2015
Same author

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Annals of oncology : official journal of the European Society for Medical Oncology·2013

High Ki-67, elevated lactate dehydrogenase (LDH), and T-cell lineage predict poor outcomes in diffuse small cleaved-cell lymphoma (DSCL) patients. These factors are crucial for understanding prognosis in this uncommon non-Hodgkin

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Diffuse small cleaved-cell lymphoma (DSCL) is a rare non-Hodgkin's lymphoma (NHL) subtype in the US.
  • DSCL is unique among intermediate-grade NHLs due to the absence of a known curable subset.
  • Limited recent research exists on prognostic factors for DSCL.

Purpose of the Study:

  • To identify laboratory data that can predict clinical outcomes in DSCL.
  • To correlate specific biological markers with patient survival.
  • To investigate prognostic indicators in a cohort of DSCL patients.

Main Methods:

  • Analysis of 33 DSCL cases collected over 12 years.
  • Correlation of morphology, immunohistochemistry (Ki-67, cell lineage), and serum lactate dehydrogenase (LDH) with clinical data.

Related Experiment Videos

  • Statistical analysis to determine associations between markers and patient survival.

    • Main Results:

    • High proliferative rate (Ki-67 ≥ 20%) significantly reduced median survival (20 vs. 80 months).
    • T-cell lineage tumors showed shorter median survival compared to B-cell neoplasms (20 vs. 40 months).
    • Elevated serum LDH (> 225 IU/L) was associated with significantly poorer median survival (8 vs. 40 months).
    • Blastoid morphology trended towards poorer outcomes (P = .08).

    Conclusions:

    • High Ki-67, elevated LDH, and T-cell lineage are significant predictors of poor outcome in DSCL.
    • These markers can help stratify patients and inform prognosis.
    • Further research may refine prognostic models for DSCL.